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In Germany, starting in 2011, legislation gave new critical impor-
tance to beneﬁt assessments through the Act on the Reform of the
Market for Medicinal Products (Arzneimittelneuordnungsgesetz
[AMNOG]) [1,2], which was designed to better regulate reimburse-
ment and reduce national health care costs. The German Federal
Joint Committee (Gemeinsamer Bundesausschuss [G-BA]) and the
Institute for Quality and Efﬁciency in Health Care (Institut für
Qualitätssicherung und Wirtschaftlichkeit im Gesundheitswesen
[IQWiG]) are charged with evaluating a drug’s added therapeutic
value in comparison to an appropriate comparative treatment.
IQWiG acts as the scientiﬁc review body that evaluates the evidence
and recommends the extent of additional beneﬁt. G-BA is the
decision maker in terms of not only additional beneﬁt but also
determining the appropriate comparative treatment and additional
subgroups for assessment [2]. The beneﬁt decisions of G-BA affect
the subsequent price negotiations between the manufacturer and
the National Association of Statutory Health Insurance Funds (i.e.,
GKV-Spitzenverband), and therefore have an enormous impact on
health care provision. G-BA and IQWiG set their own methods [3,4]
and require signiﬁcant additional information compared with that
generated during regulatory development. One element of this
additional information is the assessment of the additional sub-
groups [5].
G-BA decisions regarding additional beneﬁt claim to be
grounded in evidence-based medicine (EBM). EBM, however, should
not be used to cut health care costs, as was stated as early as 1996
[6]. Some might argue that subgrouping is more prominent in cost-
effectiveness than in clinical effectiveness, thereby being useful in
containing national health care budgets [7]. Its ad hoc applicationht & 2014, International Society for Pharmacoecon
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Open access under CC BY-NC-ND license.in the context of EBM, however, as a means to cut costs carries the
risk of misuse of EBM. In this commentary, we draw conclusions
from current subgrouping experience in early beneﬁt assessments
(EBAs) in Germany. We also challenge the validity of applying
subgrouping in the context of EBAs, and whether subgrouping
should be used to support decisions of such national importance as
drug reimbursement.Subgrouping Practice from G-BA
Fifty-eight EBAs were ﬁnalized up until December 1, 2013. A total
of 107 subgroups were differentiated within the EBAs. An addi-
tional beneﬁt was assigned to 43 (40.2%) subgroups. No additional
beneﬁt was assigned to 64 (59.8%) subgroups.
Sex, age, disease severity, and disease state are the predeﬁned
subgroups required by G-BA [8]. Additional subgroups might be
assigned as appropriate to target products to patients who beneﬁt
most. Speciﬁc additional subgroupings were required by G-BA to
conduct so-called slicing of populations from, for example,
licensing trials (e.g., boceprevir, cabazitaxel, ﬁngolimod, microbial
collagenase, telaprevir, and ticagrelor), and also to apply more
than one appropriate comparative treatment to different stages
of disease/disease entities (e.g., ﬁngolimod, microbial collage-
nase, ticagrelor, boceprevir, vismodegib, and pertuzumab) [9].
The above reasons to demand ad hoc subgroups may help
determine those groups experiencing maximal beneﬁt from a drug,
albeit purely in an exploratory context, not in a conﬁrmatory one.
Although it is reasonable to exclude those patients not experiencing
a true beneﬁt from treatment, the key challenge is how to address
those who may possibly experience a true beneﬁt—that is, those
possibly without speciﬁcally tailored conﬁrmatory evidence.omics and Outcomes Research (ISPOR).
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Table 1 – Characteristics of appropriate and inap-
propriate subgroup analyses for decision making in
drug reimbursement (modiﬁed from Sun et al. [20]).
Appropriate Inappropriate
 Tests a hypothesis (conﬁrmatory
analysis)
 No hypothesis (exploratory
analysis)
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The subgroups in EBAs as determined by G-BA were often
questionably small from a statistical perspective and had low
credibility. Subgroup analyses were generally conducted post hoc,
often not based on plausible hypotheses, lacked biologic ration-
ale, and had a high risk of multiplicity. More speciﬁcally: Prospectively deﬁned analyses
 Based on biologic rationale or at
 Ad hoc analyses
 Controversial biologic1.least solid experience
 Small number of prospectively
deﬁned subgroups tested (r5)
rationale; no experience
 High number of ad hoc
subgroups (45): increased
risk of multiplicityThe size of many of the evaluated subgroups was very small,
which has implications for statistical power. A clinical trial
is not necessarily powered to prove subgroup-treatment inter-
actions. A failure to detect a true treatment effect (type 2 error) is
more likely in subgroups because the data are subdivided into
smaller data sets, each with a reduced power to detect a treat-
ment effect. For example, G-BA separately analyzed the beneﬁt of
boceprevir for treatment-naive patients with hepatitis C and
hepatic cirrhosis. The manufacturer in the boceprevir dossier
stated that less than 1% of the patients fulﬁlled those criteria.
Furthermore, an estimate provided by the manufacturer showed
that approximately 7 patients/year in Germany were identiﬁed
who experienced hepatic cirrhosis related to hepatitis C, but had
not received any speciﬁc treatment [9]. Conﬁrmatory statistics on
such small patient numbers are inappropriate. In another EBA,
G-BA suggested to separately analyze the effect of pertuzumab in
patients with nonvisceral breast cancer [9]. A total of 808 patients
were enrolled in the respective trial, with 178 of these patients
having nonvisceral disease. The assessment of overall survival
included a total of 165 deaths, with 33 events occurring in
patients with nonvisceral disease. Assuming an equal effect of
pertuzumab on visceral and nonvisceral patients, an appropri-
ately powered analysis of nonvisceral patients would also require
a trial with approximately 800 patients instead of the 178
patients in the nonvisceral subgroup assessed by G-BA.
The additional beneﬁt of microbial collagenase to treat Dupuyt-
ren’s disease, for example, was assessed according to disease
burden as determined by Tubiana stages [9]. Only 17 patients (15
active; 2 placebo) of the largest trial and only 1 patient (active) in
another trial, however, had the highest Tubiana stage, which
accounted for a mere 6% and 2% of the overall trial population,
respectively [9]. The subgroup sizes suggested for other EBAs (e.
g., ﬁngolimod and vismodegib) were also notably small [9].2. Many subgroups in EBAs have not been deﬁned a priori and
therefore do not constitute conﬁrmatory analyses (e.g., ﬁngo-
limod, microbial collagenase, and ticagrelor [9]). Furthermore,
a high number of subgroups are often tested (e.g., telaprevir,
ticagrelor, and boceprevir), increasing the risk of multiplicity
[9]. Multiple testing of subgroups increases the chance of an
effect being mistakenly classiﬁed as a signiﬁcant treatment
effect (type 1 error).3. Many subgroups separately assessed by G-BA were not char-
acterized by differing treatment effects in the respective
Summary of Product Characteristics. For example, the Sum-
mary of Product Characteristics does not necessarily suggest
different effects of boceprevir according to cirrhosis status or
cabazitaxel based on age [10]. Nevertheless, all these sub-
groups were evaluated separately by G-BA and IQWiG [9].4. Subgrouping as conducted by G-BA was not necessarily based
on a sound biologic rationale. Telaprevir, for example, was
shown beneﬁcial in terms of sustained virologic response across
patient groups irrespective of cirrhosis status, and the effect of
ticagrelor was consistent across acute coronary syndromes as
well as randomized treatment pathways [10]. Nevertheless,
these additional subgroup assessments were required [9].
Efforts frommanufacturers to develop targeted medicines have
also not been recognized by G-BA. Ipilimumab and vemurafenibare, for example, both indicated for the treatment of melanomas.
Vemurafenib speciﬁcally and exclusively targets BRAFV600
mutation-positive melanomas, leading to signiﬁcant increases in
response rates in comparison with nonpersonalized treatments
[11]. Nevertheless, both speciﬁc and nonspeciﬁc treatments have
been rated as having signiﬁcant additional beneﬁt by G-BA [9],
without recognizing higher response rates of targeted medicine.Future Outlook for Appropriate Subgroup Analyses
The credibility of subgroup analyses has generally been ques-
tioned and, if performed inappropriately, can be extraordinarily
misleading [12–16]. Therefore, subgroup assessments in the
framework of EBAs should follow internationally established
guidelines and respective publications for appropriate analyses
[17–20]. Considerations for the development of an appropriate
framework for such analyses are listed in Table 1, and also
include the following:1. Decisions on reimbursement should preferably be based on
statistically powered, prospectively deﬁned analyses and
populations.2. If subgroup analyses are conducted, a biologic rationale
should be given (or at least be based on solid experience)
and corresponding stratiﬁcation factors should be deﬁned at
study randomization. In the absence of conﬁrmatory sub-
group evaluations, the best estimate of an effect should be
from the overall population [17].3. G-BA and IQWiG advice on required subgroup analyses should
be shifted to earlier in the regulatory process, that is, into
phase II-III development [21]. At present, this advice is usually
given after ﬁnalization of the phase III program (1 year before
market authorization). The more recent possibility of joint
advice from G-BA and regulatory authorities could be an
important step forward toward harmonizing market author-
ization and market access requirements [22].4. An additional approach focusing on personalized medicine to
target treatments to those experiencing the most therapeutic
beneﬁt comes from the German Ministry of Education and
Research [23]. Results from well-conducted and purpose-
driven research on personalized medicine should be recog-
nized by the G-BA as a suitable option to efﬁciently and
ethically target treatments.Conclusions
Ad hoc subgroup analyses from G-BA and IQWiG are not appro-
priate for making national drug reimbursement decisions.
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 3 0 7 – 3 0 9 309Underpowered, nonprospectively deﬁned slicing procedures seek
to decrease the size of reimbursed indications and thereby
exclude patients who may experience beneﬁt from treatment.
Thus, subgroup analyses are ethically disputable because they
may lead to biased treatment decisions. Such slicing procedures
abuse EBM. Although pioneers of EBM recognized that EBM could
provide useful information even in the face of deepening con-
cerns about health care costs [24], they warned that such
information might be used to inappropriately cut costs [6].
Consequently, subgrouping standards speciﬁc to AMNOG are
urgently needed, and joint G-BA/regulatory advice earlier in the
drug development process is desirable.
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